These results combined with our identification of RPL35A as a potent growth inhibitor in three independent cancer cell lines and the correlation of the poor survival of ovarian, breast, and lung cancer patients with the high expression of RPL35A, suggest that RPL35A is a key factor for survival of cancer cells, while normal cells are better protected from the effects of RPL35A depletion. Here, RPL35A is linked to lung carcinoma.